NCT03071757: A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03071757
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Has known uncontrolled metastases to the central nervous system (CNS).
https://ClinicalTrials.gov/show/NCT03071757

Comments are closed.

Up ↑